

Perlmutter Cancer Center

NYU Langone Health Presentations at ASCO
June 1, 2026

Session: Melanoma/Skin Cancers

Title: Individualized neoantigen therapy intismeran autogene (intismeran) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.

Senior Author: Janice Mehnert, MD

Time: 8:00-8:12AM

Location: S100bc

Abstract Number: 9500

Session: Hematologic Malignancies, Geriatric Oncology

Title: Beyond Del(17p): A Modern Framework for Defining High-Risk Myeloma

Chair: Gareth Morgan, MD

Time: 6/1/2026, 8:00-8:15AM

Location: S102

Session: Genitourinary Cancer—Kidney and Bladder

Title: Initial results from EXCEED, a phase 1 study of LY4101174, an antibody-drug conjugate targeting Nectin-4, in participants with advanced or metastatic urothelial carcinoma

Co-Author: Kristin Spencer, DO

Time: 8:00-9:30AM

Location: Hall D2

Abstract Number: 4517

Session: Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer

Title: A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy-naïve recurrent and/or metastatic androgen receptor (AR)-positive salivary gland cancer (ETCTN 10553)

Co-Author: Zujun Li, MD

Time: 8:48-9:00AM

Location: E450b

Abstract Number: 6012

Session: Quality Care/Health Services Research

Title: Body mass index and mortality in immune checkpoint inhibitor-treated cancers: A real-

world propensity-matched analysis

Co-Author: Ghulam Shah, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: 11069

Session: Quality Care/Health Services Research

Title: Neurological immune-related adverse events and overall survival in patients with advanced solid tumors treated with immune checkpoint inhibitors in a global real-world analysis

Co-Author: Ghulam Shah, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: 11165

Session: Gynecologic Cancer

Title: Fern-EC-01 (BNT323-01): A phase 3 trial of trastuzumab pamirtecan (HER2 ADC) versus investigator's choice of chemotherapy in patients with previously treated, HER2-expressing, recurrent endometrial cancer (EC)

Co-Author: Bhavana Pothuri, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: TPS5645

Session: Gynecologic Cancer

Title: FRAmework-01: A two-part phase 3 study of sofetabart mipitecan versus chemotherapy or mirvetuximab soravtansine in platinum-resistant ovarian cancer (PROC), and sofetabart mipitecan plus bevacizumab versus platinum-based chemotherapy plus bevacizumab in platinum-sensitive ovarian cancer (PSOC)

Senior Author: Bhavana Pothuri, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: TPS5644

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

Title: Preliminary results of an open-label, single-arm phase 2/3 trial (SPARK-ALL) of calaspargase pegol in adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia

Co-Author: Maher Abdul Hay, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: 6529

Session: Medical Education and Professional Development

Title: Leader-member exchange (LMX) and workforce outcomes in radiation oncology: A preliminary generational comparison

First Author: Christopher Mendez

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: 9038

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Title: Frontline intensified vs standard immunochemotherapy in high-risk diffuse large B-cell lymphoma: A systematic review and meta-analysis.

First Author: Lauren Scarpetti, MD

Senior Author: Samuel Yamshon, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: 7065

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Title: Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CAR T-cell therapy.

First Author: Samuel Yamshon, MD

Co-Author: John Leonard, MD

Time: 9:00AM-12:00PM

Location: Hall A - Posters and Exhibits

Abstract Number: 7035

Session: Melanoma/Skin Cancers

Title: Updated outcomes from STAMP: Surgically treated adjuvant Merkel cell carcinoma with pembrolizumab, a phase III trial—ECOG-ACRIN EA6174.

First Author/Presenter: Janice Mehnert, MD

Time: 9:36-9:48AM

Location: S100bc

Abstract Number: LBA9505

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Title: Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001

Co-Author: Rafael Winograd, MD, PhD

Time: 1:00-1:15PM

Location: Hall D2

Abstract Number: 4012

Session: Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Title: Intracranial efficacy of tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): DeLLphi-304 phase 3 post hoc analysis

Co-Author: Salman Punekar, MD

Time: 1:15-4:15PM

Location: Hall D1

Abstract Number: 8006

Session: Breast Cancer—Local/Regional/Adjuvant

Title: Association of immunotherapy infusion timing with outcomes in early-stage triple-negative breast cancer.

First Author: Xianghui Zou, MD

Senior Author: Iris Zhi, MD

Time: 1:30-4:30PM

Location: Hall A - Posters and Exhibits

Abstract Number: 594

Session: Central Nervous System Tumors

Title: Randomized phase 2 trial of ruxolitinib in combination with radiation and temozolomide compared to radiation and temozolomide for newly diagnosed glioblastoma

Co-Author: Alexandra Miller, MD

Time: 1:30-4:30PM

Location: Hall A - Posters and Exhibits

Abstract Number: TPS2094

Session: Central Nervous System Tumors

Title: Prospective, randomized, placebo-controlled phase 2b trial of SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma (SURVIVE)

Co-Author: Marissa Barbaro, MD

Time: 1:30-4:30PM

Location: Hall A - Posters and Exhibits

Abstract Number: TPS2106

Session: Central Nervous System Tumors

Title: Final results of a single-arm, open-label, multicenter phase 2 study of the radiopharmaceutical [¹⁷⁷Lu]Lu-DOTA-TATE and [⁶⁸Ga]Ga-DOTA-TATE in adults with

advanced intracranial meningioma

Senior Author: Timothy Shepherd, MD, PhD

Time: 1:30-4:30PM

Location: Hall A - Posters and Exhibits

Abstract Number: 2090

Session: Breast Cancer—Metastatic

Title: Elacestrant in combination with capivasertib in patients with ER+/HER2– advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study

Co-Author: Nancy Chan, MD

Time: 1:30-4:30PM

Location: Hall A - Posters and Exhibits

Abstract Number:

Session: Radiation Re-Imagined: Radioligand Innovation in Prostate Cancer

Title: CONVERGE-01 part 3: Ac-225 rosopatamab tetraxetan (CONV01- α) in Lu-PSMA-pretreated metastatic castration-resistant prostate cancer (mCRPC)

Co-Author: David Wise, MD

Time: 3:48-4:00PM

Location: Arie Crown Theater

Abstract Number: 5011